BofA analyst Travis Steed raised the firm’s price target on ShockWave Medical to $310 from $275 and keeps a Buy rating on the shares after it was posted to clinicaltrials.gov that FORWARD PAD, ShockWave’s pivotal study for Javelin Peripheral, completed enrollment at 75 patients five months faster than expected. The firm thinks the fact that the trial enrolled so quickly is likely a good indicator for commercial uptake and it raised its price target on the shares given rising peer multiples, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SWAV:
- ShockWave Medical price target raised to $286 from $260 at Needham
- ShockWave Medical price target raised to $290 from $275 at Piper Sandler
- ShockWave Medical price target raised to $263 from $215 at Canaccord
- ShockWave Medical sees FY24 revenue $910M-$930M, consensus $918.91M
- ShockWave Medical reports Q4 EPS $1.16, consensus 89c